Reshaping CAR-T cells through overexpression of T cell factor 1
Overexpression of TCF-1 confers resistance to apoptosis, limits excessive activation, and promotes a less differentiated phenotype, collectively enhancing CAR-T cell persistence and long-term efficacy. These findings suggest that TCF-1 modulation represents a promising strategy to improve durability and safety of CAR-T cell therapy in relapsed or refractory hematologic malignancies.
Authors
- Michaël Schmitt (ORCID: https://orcid.org/0000-0002-7386-8092)
- David Sedloev
- Carsten Müller‐Tidow (ORCID: https://orcid.org/0000-0002-7166-5232)
- Yuntian Ding
- Huixiu Han
- Tim Sauer (ORCID: https://orcid.org/0000-0001-5412-324X)
- Qian Chen (ORCID: https://orcid.org/0000-0002-1487-5479)
- Lei Wang (ORCID: https://orcid.org/0000-0003-1477-2725)
- Hao Yao (ORCID: https://orcid.org/0000-0002-5246-5550)
- Anita Schmitt
Institutions
- Sun Yat-sen University (CN)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Heidelberg University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1623869
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00